ELI LILLY AND COMPANY Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax
ELI LILLY AND COMPANY (LLY) reported Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax of $886.10 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-19.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax · last filed 2014-02-19
- ELI LILLY AND COMPANY other comprehensive income (loss), defined benefit plan, gain (loss) arising during period, tax for fiscal 2013 was $886.10M, a 2475.87% increase from fiscal 2012.
- ELI LILLY AND COMPANY other comprehensive income (loss), defined benefit plan, gain (loss) arising during period, tax for fiscal 2012 was $34.40M.
- ELI LILLY AND COMPANY other comprehensive income (loss), defined benefit plan, gain (loss) arising during period, tax for fiscal 2011 was -$383.80M, a 735.43% decline from fiscal 2010.
- ELI LILLY AND COMPANY other comprehensive income (loss), defined benefit plan, gain (loss) arising during period, tax for fiscal 2010 was $60.40M.
| Period end | Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax 12 month | Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax 12 month as first filed |
|---|---|---|
| 2013-12-31 | $886.10M 10-K · filed 2014-02-19 | |
| 2012-12-31 | $34.40M 10-K · filed 2014-02-19 | |
| 2011-12-31 | -$383.80M 10-K · filed 2014-02-19 | $383.80M 10-K · filed 2012-02-24 |
| 2010-12-31 | $60.40M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |